Medpace (MEDP) Competitors $295.77 -10.85 (-3.54%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$299.75 +3.98 (+1.35%) As of 06:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MEDP vs. IQV, CPAY, GIB, TOST, AER, GRAB, RDDT, RBA, GFL, and TRUShould you be buying Medpace stock or one of its competitors? The main competitors of Medpace include IQVIA (IQV), Corpay (CPAY), CGI (GIB), Toast (TOST), AerCap (AER), Grab (GRAB), Reddit (RDDT), RB Global (RBA), GFL Environmental (GFL), and TransUnion (TRU). These companies are all part of the "business services" industry. Medpace vs. IQVIA Corpay CGI Toast AerCap Grab Reddit RB Global GFL Environmental TransUnion Medpace (NASDAQ:MEDP) and IQVIA (NYSE:IQV) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, community ranking, dividends, analyst recommendations, institutional ownership and valuation. Is MEDP or IQV more profitable? Medpace has a net margin of 19.17% compared to IQVIA's net margin of 8.91%. Medpace's return on equity of 51.48% beat IQVIA's return on equity.Company Net Margins Return on Equity Return on Assets Medpace19.17% 51.48% 20.47% IQVIA 8.91%28.81%7.02% Which has better valuation & earnings, MEDP or IQV? IQVIA has higher revenue and earnings than Medpace. IQVIA is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMedpace$2.16B3.94$404.39M$13.1022.58IQVIA$15.50B1.53$1.37B$7.3418.71 Does the MarketBeat Community favor MEDP or IQV? IQVIA received 333 more outperform votes than Medpace when rated by MarketBeat users. Likewise, 68.12% of users gave IQVIA an outperform vote while only 62.81% of users gave Medpace an outperform vote. CompanyUnderperformOutperformMedpaceOutperform Votes35362.81% Underperform Votes20937.19% IQVIAOutperform Votes68668.12% Underperform Votes32131.88% Does the media prefer MEDP or IQV? In the previous week, IQVIA had 8 more articles in the media than Medpace. MarketBeat recorded 28 mentions for IQVIA and 20 mentions for Medpace. Medpace's average media sentiment score of 1.54 beat IQVIA's score of 1.29 indicating that Medpace is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 16 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive IQVIA 20 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, MEDP or IQV? Medpace has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500. Comparatively, IQVIA has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500. Do institutionals & insiders have more ownership in MEDP or IQV? 78.0% of Medpace shares are owned by institutional investors. Comparatively, 89.6% of IQVIA shares are owned by institutional investors. 20.3% of Medpace shares are owned by company insiders. Comparatively, 1.6% of IQVIA shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts recommend MEDP or IQV? Medpace presently has a consensus price target of $349.30, suggesting a potential upside of 18.10%. IQVIA has a consensus price target of $228.14, suggesting a potential upside of 66.12%. Given IQVIA's stronger consensus rating and higher possible upside, analysts plainly believe IQVIA is more favorable than Medpace.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medpace 0 Sell rating(s) 10 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.23IQVIA 0 Sell rating(s) 7 Hold rating(s) 16 Buy rating(s) 1 Strong Buy rating(s) 2.75 SummaryIQVIA beats Medpace on 10 of the 19 factors compared between the two stocks. Get Medpace News Delivered to You Automatically Sign up to receive the latest news and ratings for MEDP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MEDP vs. The Competition Export to ExcelMetricMedpaceCommercial physical research IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.50B$3.00B$5.37B$8.39BDividend YieldN/A2.27%5.22%4.10%P/E Ratio23.42109.8026.8419.71Price / Sales3.94162.05392.34117.39Price / Cash24.7234.5738.2534.62Price / Book10.912.356.794.50Net Income$404.39M$118.81M$3.23B$248.18M7 Day Performance-0.22%-3.41%1.53%0.20%1 Month Performance4.78%-3.43%10.06%12.37%1 Year Performance-24.13%-17.71%16.72%7.04% Medpace Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MEDPMedpace4.6961 of 5 stars$295.77-3.5%$349.30+18.1%-25.4%$8.50B$2.16B23.425,200Positive NewsIQVIQVIA4.9341 of 5 stars$156.09+4.8%$231.71+48.4%-40.1%$27.00B$15.50B20.8186,000Positive NewsAnalyst ForecastHigh Trading VolumeCPAYCorpay4.3462 of 5 stars$349.68+6.8%$395.07+13.0%+20.1%$24.57B$4.05B25.0110,500Positive NewsGIBCGI3.8068 of 5 stars$107.99+1.9%$156.75+45.2%+2.3%$24.48B$15.14B19.5390,000Positive NewsTOSTToast2.619 of 5 stars$42.85+4.9%$40.91-4.5%+61.3%$21.31B$5.22B-4,280.324,500Positive NewsHigh Trading VolumeAERAerCap3.4288 of 5 stars$111.37+1.6%$118.00+6.0%+22.5%$20.80B$8.06B8.82740Positive NewsGRABGrab1.844 of 5 stars$4.99+1.8%$5.60+12.1%+29.3%$20.09B$2.92B-249.509,490Gap UpRDDTReddit3.8924 of 5 stars$111.05+2.4%$140.35+26.4%+61.4%$20.09B$1.45B-14.372,013Trending NewsAnalyst ForecastInsider TradeGap DownRBARB Global2.817 of 5 stars$104.16-1.7%$114.50+9.9%+43.1%$19.29B$4.33B51.824,200Positive NewsAnalyst UpgradeGFLGFL Environmental3.375 of 5 stars$48.68-2.0%$54.14+11.2%+57.2%$19.15B$7.99B-36.6019,500Positive NewsTRUTransUnion4.8128 of 5 stars$91.81+6.6%$109.38+19.1%+7.5%$17.91B$4.26B62.8812,200Positive NewsGap Down Related Companies and Tools Related Companies IQVIA Alternatives Corpay Alternatives CGI Alternatives Toast Alternatives AerCap Alternatives Grab Alternatives Reddit Alternatives RB Global Alternatives GFL Environmental Alternatives TransUnion Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MEDP) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medpace Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medpace With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MEDP Stock Free MEDP Stock Alerts